Dimitri Arangalage1, Virginia Nguyen1, Tiphaine Robert2, Maria Melissopoulou3, Tiffany Mathieu3, Candice Estellat4, Isabelle Codogno3, Virginie Huart5, Xavier Duval6, Claire Cimadevilla7, Alec Vahanian1, Monique Dehoux2, David Messika-Zeitoun1. 1. Department of Cardiology, Bichat Hospital, Paris, France INSERM U1148, Bichat Hospital, Paris, France Faculté de Médecine Paris-Diderot, University Paris Diderot, Sorbonne Paris Cité, Paris, France. 2. Department of Biochemistry, Bichat Hospital, Paris, France. 3. Department of Cardiology, Bichat Hospital, Paris, France. 4. Department of Epidemiology, Biostatistic and Clinical Research, Bichat Hospital, Paris, France. 5. Centre de Ressources Biologiques, Bichat Hospital, Paris, France. 6. Centre d'Investigation Clinique, Bichat Hospital, Paris, France. 7. Department of Cardiac Surgery, Bichat Hospital, Paris, France.
Abstract
OBJECTIVE: Myocardial fibrosis has been proposed as an outcome predictor in asymptomatic patients with severe aortic stenosis (AS) that may lead to consider prophylactic surgery. It can be detected using MRI but its widespread use is limited and development of substitute biomarkers is highly desirable. We analysed the determinants and prognostic value of galectin-3, one promising biomarker linked to myocardial fibrosis. METHODS: Patients with at least mild degenerative AS enrolled between 2006 and 2013 in two ongoing studies, COFRASA/GENERAC (COhorte Française de Rétrécissement Aortique du Sujet Agé/GENEtique du Rétrécissement Aortique), aiming at assessing the determinants of AS occurrence and progression, constituted our population. RESULTS: We prospectively enrolled 583 patients. The mean galectin-3 value was 14.3±5.6 ng/mL. There was no association between galectin-3 and functional status (p=0.55) or AS severity (p=0.58). Independent determinants of galectin-3 were age (p=0.0008), female gender (p=0.04), hypertension (p=0.002), diabetes (p=0.02), reduced left ventricular ejection fraction (p=0.01), diastolic dysfunction (E/e', p=0.02) and creatinine clearance (p<0.0001). Among 330 asymptomatic patients at baseline, galectin-3 was neither predictive of outcome in univariate analysis (p=0.73), nor after adjustment for age, gender, rhythm, creatinine clearance and AS severity (p=0.66). CONCLUSIONS: In a prospective cohort of patients with a wide range of AS severity, galectin-3 was not associated with AS severity or functional status. Main determinants of galectin-3 were age, hypertension and renal function. Galectin-3 did not provide prognostic information on the occurrence of AS-related events. Our results do not support the use of galectin-3 in the decision-making process of asymptomatic patients with AS. TRIAL REGISTRATION NUMBER: COFRASA NCT00338676 and GENERAC CT00647088. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVE:Myocardial fibrosis has been proposed as an outcome predictor in asymptomatic patients with severe aortic stenosis (AS) that may lead to consider prophylactic surgery. It can be detected using MRI but its widespread use is limited and development of substitute biomarkers is highly desirable. We analysed the determinants and prognostic value of galectin-3, one promising biomarker linked to myocardial fibrosis. METHODS:Patients with at least mild degenerative AS enrolled between 2006 and 2013 in two ongoing studies, COFRASA/GENERAC (COhorte Française de Rétrécissement Aortique du Sujet Agé/GENEtique du Rétrécissement Aortique), aiming at assessing the determinants of AS occurrence and progression, constituted our population. RESULTS: We prospectively enrolled 583 patients. The mean galectin-3 value was 14.3±5.6 ng/mL. There was no association between galectin-3 and functional status (p=0.55) or AS severity (p=0.58). Independent determinants of galectin-3 were age (p=0.0008), female gender (p=0.04), hypertension (p=0.002), diabetes (p=0.02), reduced left ventricular ejection fraction (p=0.01), diastolic dysfunction (E/e', p=0.02) and creatinine clearance (p<0.0001). Among 330 asymptomatic patients at baseline, galectin-3 was neither predictive of outcome in univariate analysis (p=0.73), nor after adjustment for age, gender, rhythm, creatinine clearance and AS severity (p=0.66). CONCLUSIONS: In a prospective cohort of patients with a wide range of AS severity, galectin-3 was not associated with AS severity or functional status. Main determinants of galectin-3 were age, hypertension and renal function. Galectin-3 did not provide prognostic information on the occurrence of AS-related events. Our results do not support the use of galectin-3 in the decision-making process of asymptomatic patients with AS. TRIAL REGISTRATION NUMBER: COFRASA NCT00338676 and GENERAC CT00647088. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Germán E González; N-E Rhaleb; Martin A D'Ambrosio; Pablo Nakagawa; Tang-Dong Liao; Edward L Peterson; Pablo Leung; Xiangguo Dai; Branislava Janic; Yun-He Liu; Xiao-Ping Yang; Oscar A Carretero Journal: Am J Physiol Heart Circ Physiol Date: 2016-08-05 Impact factor: 4.733
Authors: Jakub Baran; Łukasz Niewiara; Jakub Podolec; Mateusz Siedliński; Ewelina Józefczuk; Anna Bernacik; Rafał Badacz; Tadeusz Przewłocki; Piotr Pieniążek; Krzysztof Żmudka; Jacek Legutko; Anna Kabłak-Ziembicka Journal: J Cardiovasc Dev Dis Date: 2022-06-17
Authors: Frederique E C M Peeters; Elton A M P Dudink; Bob Weijs; Larissa Fabritz; Winnie Chua; Bas L J H Kietselaer; Joachim E Wildberger; Steven J R Meex; Paulus Kirchhof; Harry J G M Crijns; Leon J Schurgers Journal: Front Cell Dev Biol Date: 2020-07-10
Authors: Hannah Z R McConkey; Michael Marber; Amedeo Chiribiri; Philippe Pibarot; Simon R Redwood; Bernard D Prendergast Journal: Circ Cardiovasc Interv Date: 2019-08-16 Impact factor: 6.546